Home > Insider Trading > Filing (0000950170-25-057996)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1812364	Relay Therapeutics Inc.	RLAY	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1816210	Sanjiv Patel	C/O Relay Therapeutics, Inc. 399 Binney Street, 2Nd Floor Cambridge MA 02142	President And Ceo	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2025-04-23	42,769	$2.97	840,320	No	4	S	Direct
Common Stock	Disposition	2025-04-23	18,653	$2.97	821,667	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	199,548	Indirect	By The Patel Family Irrevocable Trust of 2019
Common Stock	687,355	Indirect	By The SSP Irrevocable Trust of 2020

Footnotes

Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 95,295 shares of restricted stock units ("RSUs") on April 22, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.
Includes 452,118 shares underlying RSUs.
Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 41,558 shares of RSUs on April 22, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.
Includes 410,560 shares underlying RSUs.
These shares are held in irrevocable trusts for the benefit of the reporting person's family members. An independent trustee is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.